Orthopedic oncology is a surgical subspecialty focused on diagnosing and treating tumors that grow in bones, joints, muscles, and the surrounding soft tissues. These tumors range from harmless growths that never need treatment to aggressive cancers like osteosarcoma and Ewing sarcoma. Orthopedic oncologists also manage bone damage caused by cancers that started elsewhere in the body, such as breast, prostate, or lung cancer spreading to the skeleton.
Conditions Orthopedic Oncologists Treat
The specialty covers a wide spectrum. On one end are benign bone tumors, which are noncancerous growths like bone cysts, osteoid osteomas, and fibrous dysplasia. Many of these are found incidentally on an X-ray taken for something else entirely. Some never need treatment. Others, like giant cell tumors and chondroblastomas, grow aggressively enough to destroy surrounding bone or damage nearby joints, making surgical removal necessary.
On the other end are primary bone cancers, meaning cancers that originate in bone or cartilage. The most common include osteosarcoma, Ewing sarcoma, and chondrosarcoma. These are rare compared to cancers of the breast, lung, or colon, but they require highly specialized surgical planning because the tumor is embedded in structural tissue that the body depends on for movement and support.
Soft tissue sarcomas also fall within this specialty. These cancers develop in muscles, fat, nerves, or blood vessels near the skeleton. Types include rhabdomyosarcoma, synovial sarcoma, and leiomyosarcoma. And a large portion of an orthopedic oncologist’s workload involves metastatic bone disease, where cancer from another organ spreads to the skeleton. Breast, prostate, lung, and thyroid cancers are the most frequent sources. Surgery in these cases aims to stabilize weakened bones, prevent fractures, and relieve pain.
Primary Bone Cancers by Type
Each major bone cancer has a distinct profile in terms of who it affects and where it appears.
Osteosarcoma is the most common bone cancer in children and adolescents, accounting for about 56% of bone cancers in that age group. It typically develops near the growth plates of long bones, especially the lower thighbone, upper shinbone, and upper arm bone. In adults, it more often affects the spine and pelvis. Five-year survival rates range from 60 to 75% when the disease is caught before it spreads, dropping to 5 to 30% once it has metastasized.
Ewing sarcoma is an aggressive cancer with a peak incidence around age 15. Unlike osteosarcoma, which grows near the ends of bones, Ewing sarcoma develops along the shaft. It most commonly appears in the long bones of the leg, the pelvis, and the ribs or spine. The tumor is driven by a specific chromosomal rearrangement present in more than 85% of cases, which helps pathologists confirm the diagnosis.
Chondrosarcoma is primarily a disease of adults between 30 and 60. It produces cartilage and tends to be slower growing than osteosarcoma or Ewing sarcoma, rarely spreading to other organs. It appears most often in the long bones, pelvis, ribs, and shoulder blade.
How These Tumors Are Diagnosed
Every suspicious bone or soft tissue lesion is treated as potentially malignant until proven otherwise. The diagnostic process starts with imaging. Plain X-rays often catch the first sign, but MRI and CT scans provide the detailed information surgeons need to understand the tumor’s size, location, and relationship to nerves and blood vessels.
Biopsy comes after imaging is complete, not before. This sequencing matters because a biopsy creates a needle track or incision that must be carefully placed along the path of any future surgery. If a biopsy is done carelessly or in the wrong location, it can compromise the surgical options later. The imaging, biopsy, and eventual surgery are ideally planned together from the start.
Core-needle biopsy, guided by ultrasound or CT, is considered the gold standard. The needle extracts a small cylinder of tissue that preserves the tumor’s internal structure, allowing pathologists to determine the specific tumor type, grade it, and run molecular tests. Complication rates are low, under 11%. Fine-needle aspiration, which collects only individual cells, has a limited role in musculoskeletal tumors because it often can’t provide enough tissue for the detailed analysis these diagnoses require. If a core biopsy doesn’t yield a clear answer, an open surgical biopsy may follow.
The Tumor Board Approach
Musculoskeletal tumors are rarely managed by a single doctor. Cases are reviewed by a multidisciplinary tumor board that typically includes a musculoskeletal radiologist, a pathologist, a medical oncologist, a radiation oncologist, a surgical oncologist, and sometimes a pediatric oncologist and a geneticist. The radiologist presents the imaging and highlights what’s concerning. The pathologist explains what the tissue sample shows at the cellular level. Treating clinicians then bring specific surgical or treatment questions to the group for collective input.
This team-based model exists because musculoskeletal tumors are uncommon, and getting the diagnosis and staging right the first time is critical. A misread MRI or a misclassified biopsy can lead to the wrong surgery, which in bone and soft tissue cancer can mean the difference between saving a limb and losing one.
Surgery: Limb Salvage and Reconstruction
The development of limb-sparing surgery transformed orthopedic oncology. Before modern reconstruction techniques existed, amputation was the standard treatment for bone cancer in an arm or leg. Today, limb salvage is the goal whenever possible. The decision between saving and amputating a limb depends on the extent of soft tissue damage, whether major nerves and blood vessels are involved, the patient’s overall health, and the resources available at the treating center.
When a section of bone is removed along with a tumor, the gap has to be rebuilt. Several approaches exist. Modular endoprostheses are metal implants, most commonly made of titanium or tantalum, that replace the removed bone segment and sometimes the adjacent joint. These devices were a major catalyst in making limb salvage the standard of care for extremity sarcomas. Porous metal coatings on these implants encourage the patient’s own bone to grow into the surface, improving long-term stability.
Bone allografts, donor bone from a tissue bank, offer another option. They allow a more anatomical reconstruction and provide natural attachment points for tendons and ligaments, which improves joint stability and function. Advanced 3D imaging now helps surgeons select donor bone that closely matches the patient’s anatomy.
3D-printed implants represent a newer frontier. Custom scaffolds can be designed from the patient’s own CT scans and printed from biocompatible materials. Some are made from synthetic materials that gradually dissolve as the patient’s own bone grows in to replace them. In rare cases, surgeons have even used the patient’s own body as a living incubator, implanting a custom scaffold packed with bone-growth factors into a muscle to grow new bone before transplanting it to the surgical site.
Managing Benign Tumors
Not every bone tumor requires surgery. Fibrous dysplasia, one of the more common benign bone tumors, generally doesn’t need an operation unless the growth weakens the bone enough to risk a fracture. Aneurysmal bone cysts can sometimes be treated with repeated injections of medication rather than open surgery.
Other benign tumors do need removal. Giant cell tumors grow aggressively and are almost always treated surgically. Chondroblastomas affect areas near joints in children and cause significant pain, so they’re typically removed. Osteoid osteomas, which cause intense nighttime pain that responds well to over-the-counter anti-inflammatory medications, can be treated with radiofrequency ablation, a minimally invasive procedure that uses heat to destroy the tumor without a large incision.
Training and Specialization
Becoming an orthopedic oncologist requires completing a five-year orthopedic surgery residency followed by a 12-month fellowship specifically in musculoskeletal oncology, as outlined by the Accreditation Council for Graduate Medical Education. One unusual aspect of this subspecialty: no board of the American Board of Medical Specialties currently offers a certification exam in musculoskeletal oncology, so completing the fellowship itself is the primary credential. Fellowship applicants are informed of this before they enter training.
The rarity of these tumors means that orthopedic oncologists are concentrated at large academic medical centers and specialized cancer hospitals. Patients with a suspected bone or soft tissue tumor are often referred to one of these centers for biopsy and treatment planning, even if their initial care started at a community hospital.